SOURCE-LINKED STUDY SUMMARY
Mots-c attenuates diabetic nephropathy by downregulating LARS1 to promote lipophagy and suppress tubular senescence.
Abstract summarizedQuality not appraised
- What was studied
- Preclinical experiments tested whether MOTS-c protects against diabetic kidney injury through lipid-droplet clearance.
- Who / model studied
- Diabetic db/db mice and HK-2 kidney cells. This was not an administered-human trial.
- Studied dose & schedule
- MOTS-c treatment with LARS1-overexpression and autophagy-inhibition experiments. Dose, route, frequency, duration and sample sizes were unavailable in the abstract.
- What the study found
- Urinary albumin/creatinine and tissue-injury findings improved alongside reduced lipid accumulation and senescence markers. LARS1 overexpression blocked protective cell effects; an autophagy inhibitor largely reversed protection in mice.
- Limitations & context
- Abstract-based assessment with no numerical effect sizes, uncertainty estimates or safety counts available. Pathway-interference experiments support a mechanistic hypothesis but do not prove a uniquely specific pathway. Human kidney benefit and clinical safety remain unestablished.
Read summary source ↗ · Prepared 10/28/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.bcp.2026.118572